Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CERo Therapeutics HoldingsCERO +0.89% 3-Year EBITDA Growth Rate is 87.40% as of Mar. 2026, which is at its 10-year median of 87.40. The stock has 2 warning signs investors should review. Among 1,130 Biotechnology companies, CERo Therapeutics Holdings ranks better than 97.79% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 87.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of CERo Therapeutics Holdings was 87.40% per year. The lowest was 87.40% per year. And the median was 87.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
CERo Therapeutics Holdings 3-Year EBITDA Growth Rate Related Terms
CERO vs PTIX, CYTOF, CARM: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, CERo Therapeutics Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CERo Therapeutics Holdings 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where CERo Therapeutics Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 87.40% mean?
CERo Therapeutics Holdings (CERO) has a 3-Year EBITDA Growth Rate of 87.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CERo Therapeutics Holdings and its competitors. This is near median its historical median of 87.40. Over the past decade, CERo Therapeutics Holdings' 3-Year EBITDA Growth Rate has ranged from 87.40 to 87.40. According to the industry distribution chart, CERo Therapeutics Holdings ranks #25 out of 1130 companies in the Biotechnology industry, placing it in the top 2.2%.
Is CERo Therapeutics Holdings' 3-Year EBITDA Growth Rate too high?
CERo Therapeutics Holdings' current 3-Year EBITDA Growth Rate of 87.40% is near median its 10-year median of 87.40. Over the past 10 years, this metric has ranged from a low of 87.40 to a high of 87.40. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. CERo Therapeutics Holdings' value of 87.40% is 488.6% above this industry median. Based on the distribution chart, CERo Therapeutics Holdings ranks #25 out of 1130 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does CERo Therapeutics Holdings' 3-Year EBITDA Growth Rate compare to PTIX and CYTOF?
According to the Biotechnology industry distribution chart, CERo Therapeutics Holdings ranks #25 out of 1130 companies for 3-Year EBITDA Growth Rate. This places CERo Therapeutics Holdings in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. CERo Therapeutics Holdings' value of 87.40% is 488.6% above this benchmark. Historically, CERo Therapeutics Holdings' own 3-Year EBITDA Growth Rate has ranged from 87.40 to 87.40 over the past decade. While the company's 10-year median is 87.40 vs. the industry median of 14.85, CERo Therapeutics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CERo Therapeutics Holdings's current 3-Year EBITDA Growth Rate of 87.40% is 488.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CERo Therapeutics Holdings and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CERo Therapeutics Holdings's current 3-Year EBITDA Growth Rate is 87.40%, which is near median its own 10-year median of 87.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CERo Therapeutics Holdings stock overvalued right now?
CERo Therapeutics Holdings (CERO) has a current 3-Year EBITDA Growth Rate of 87.40%. The current 3-Year EBITDA Growth Rate is 87.40%, which is near median its 10-year median of 87.40 and 488.6% above the Biotechnology industry median of 14.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For CERo Therapeutics Holdings (CERO), the current 3-Year EBITDA Growth Rate is 87.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CERo Therapeutics Holdings Inc is an immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. The company's molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CERO has been successfully added to your 
